Cizzle Bio Inc. founder and CEO Bill Behnke moderated a high-profile panel at the 2025 Association for Value-Based Cancer ...
Cancer treatment is no longer limited to standard protocols . The same drug, given in the same way, does not work for every ...
Novartis acquires Avidity Biosciences for $12B to boost growth and rare disease pipeline. Explore impacts, risks, and outlook ...
Heart attacks often feel sudden and shocking when they happen, but the truth is actually the opposite. Most heart attacks do ...
The drug, JSKN003, showed promising early efficacy in colorectal cancer patients in China in a Phase I/II trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback